Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →An estimated 1.5 million Americans, and at least five million people worldwide, have a form of lupus. About 322,000 adults in the United States have a definite…
Pfizer has joined Roivant in forming Priovant Therapeutics around brepocitinib, an oral dual TYK2/JAK1 inhibitor that has run Phase 2 trials in psoriasis,…
Priovant Therapeutics, a subsidiary of Roivant Sciences, today announced positive topline results from the global Phase 3 VALOR study evaluating brepocitinib…
Source summaries from our enrichment pipeline; follow links for originals.
All 15 sources with sentiment breakdown →
Roivant and Pfizer formed Priovant Therapeutics in September 2021, with Pfizer licensing global development rights and US/Japan commercial rights to brepocitinib (an oral and topical TYK2/JAK1 inhibitor) into the new "Vant" in exchange for a 25% equity stake. The JV launched with registrational programs in dermatomyositis (DM) and systemic lupus erythematosus (SLE). The two programs diverged sharply: in November 2023 the Phase 2 SLE study missed its primary endpoint (SRI-4 at week 52) against an unusually high placebo response, and Priovant discontinued brepocitinib in SLE. The DM program, by contrast, delivered the first-ever positive 52-week placebo-controlled Phase 3 in dermatomyositis (VALOR, positive topline December 2024; 241 subjects, week-52 mean TIS 46.5 vs 31.2 placebo, p=0.0006). In March 2026 the FDA accepted the brepocitinib NDA in DM and granted Priority Review, with a PDUFA target in Q3 2026 and a planned US launch at end of September 2026 — positioning brepocitinib as the potential first targeted therapy for dermatomyositis. Priovant has since expanded brepocitinib into non-infectious uveitis (Phase 3), cutaneous sarcoidosis (positive Phase 2; Phase 3 in 2026) and lichen planopilaris (Phase 2/3).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roivant Sciences Ltd. / Pfizer Inc. / Priovant Therapeutics (this deal) | 2021 | $300M | — |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| PerkinElmer, Inc. / EUROIMMUN Medizinische Labordiagnostika AG | 2017 | $1.3B | 88 |
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences | 2024 | $4.9B | 78 |
| Roche Holding AG / Genentech, Inc. (Roche Group) | 2009 | $46.8B | 72 |
| Travere Therapeutics, Inc. / Everest Medicines Limited | 2026 | $1.1B | 72 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
← Browse all deals · How we score deals
More: 2021 deals · Immunology deals